(Q36694734)

English

Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies

scientific article published on March 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 August 2017

Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies (English)

1 reference

Europe PubMed Central

15 August 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

J J Body

1

1 reference

Europe PubMed Central

15 August 2017

I J Diel

2

1 reference

Europe PubMed Central

15 August 2017

M Lichinitzer

3

1 reference

Europe PubMed Central

15 August 2017

A Lazarev

4

1 reference

Europe PubMed Central

15 August 2017

M Pecherstorfer

5

1 reference

Europe PubMed Central

15 August 2017

R Bell

6

1 reference

Europe PubMed Central

15 August 2017

D Tripathy

7

1 reference

Europe PubMed Central

15 August 2017

B Bergstrom

8

1 reference

Europe PubMed Central

15 August 2017

language of work or name

0 references

publication date

1 March 2004

1 reference

Europe PubMed Central

15 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

15 August 2017

90

1 reference

Europe PubMed Central

15 August 2017

6

1 reference

Europe PubMed Central

15 August 2017

1133-1137

1 reference

Europe PubMed Central

15 August 2017

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6601663

0 references

Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409647

30 September 2017

Effectiveness and cost of bisphosphonate therapy in tumor bone disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409647

30 September 2017

Bisphosphonates for breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409647

30 September 2017

Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409647

30 September 2017

American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409647

30 September 2017

Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409647

30 September 2017

Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409647

28 June 2018

Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409647

5 September 2018

Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409647

5 September 2018

Oral clodronate in breast cancer patients with bone metastases: a randomized study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409647

5 September 2018

Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study

1 reference

https://pubmed.ncbi.nlm.nih.gov/15026791

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/15026791

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/15026791

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/15026791

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A DISTRIBUTION-FREE k-SAMPLE TEST AGAINST ORDERED ALTERNATIVES

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6601663

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.BJC.6601663

1 reference

Europe PubMed Central

15 August 2017

1 reference

Europe PubMed Central

15 August 2017

1 reference

Europe PubMed Central

15 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36694734&oldid=1646508024"